In April it acquired Topokine Therapeutics, a clinical-stage biotech focused on topical medicines for fat reduction, for $85 million upfront, gaining XAF5, a topical agent in late-stage development for the treatment of steatoblepharon
Under the terms of the agreement, Allergan acquired Topokine Therapeutics for an upfront payment of USD 85m and success-based development and sales milestones for XAF5, a first-in-class topical agent in late-stage development for the treatment of steatoblepharon
, also known as undereye bags.
The acquisition expands Allergan's cosmetic drugs pipeline with Topokines Phase IIb/III candidate XAF5, a prospective first-in-class topical treatment for steatoblepharon
, or bags under the eyes.